Skip to main content

Advertisement

SpringerLink
Log in

Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  CAS  Google Scholar 

  2. Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 375:1823–1833

    Article  CAS  Google Scholar 

  3. Baxi S, Yang A, Gennarelli RL et al (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360:k793

    Article  Google Scholar 

  4. Fellner A, Makranz C, Lotem M et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601–609

    Article  CAS  Google Scholar 

  5. Garcia CR, Jayswal R, Adams V, Antony LB, Villano JL (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol. https://doi.org/10.1007/s12094-019-02060-8

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gómez Vicente L, Rubio Viqueira B, De Las Jimenez, Peñas M et al (2016) Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab. Neuro-oncology 18:iv25

    Article  Google Scholar 

  7. Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173

    Article  Google Scholar 

  8. Trabattoni D, Saresella M, Pacei M et al (2009) Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 183:4984–4993

    Article  CAS  Google Scholar 

  9. Takizawa S, Kaneyama T, Tsugane S et al (2014) Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler’s murine encephalomyelitis virus-induced demyelinating disease. J Neuroimmunol 274:78–85

    Article  CAS  Google Scholar 

  10. Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med 380:1597–1605

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy

    Marzia Anita Lucia Romeo, Lucia Moiola, Vittorio Martinelli & Massimo Filippi

  2. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Marina Chiara Garassino & Giulia Galli

  3. Department of Neurophysiology, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Giancarlo Comi

  4. Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Massimo Filippi

  5. Vita-Salute San Raffaele University, Milan, Italy

    Massimo Filippi

Authors
  1. Marzia Anita Lucia Romeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina Chiara Garassino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucia Moiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulia Galli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giancarlo Comi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vittorio Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Massimo Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: MALR; writing—original draft preparation: MALR; acquisition of data: MARL, MAG, LM, GG; interpretation of data: all authors; writing—review, and editing: all authors.

Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Conflicts of interest

M. Romeo received honoraria from Sanofi Genzyme, Merck-Serono, and support for traveling from Novartis, Almirall and Teva Pharmaceutical Industries; M. Garassino received personal fees from AstraZeneca, Roche, BMS, MSD; L. Moiola received honoraria from Sanofi Genzyme, TEVA Pharmaceutical Industries, Novartis, Merck-Serono and Biogen Idec; G. Galli report no disclosures; G. Comi received compensation for consulting services and speaking activities from Novartis, Teva Pharmaceutical Industries, Sanofi Genzyme, Merck-Serono, Biogen Idec, Roche, Almirall, Celgene, Forward Pharma, Medday and Excemed; V. Martinelli received honoraria from Sanofi Genzyme, Biogen Idec, TEVA Pharmaceutical Industries, Bayer, Merck-Serono and Novartis; M. Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).

Ethical standards

A written informed consent was obtained from the patient for the publication of this case.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romeo, M.A.L., Garassino, M.C., Moiola, L. et al. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol 266, 3163–3166 (2019). https://doi.org/10.1007/s00415-019-09562-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-019-09562-z

Search

Navigation